On November 12, GIANT BIOGENE fell 4.04% in regular trading, trading at HK$20.44, with turnover of HK$46.56 million.
The immediate catalyst was the latest MSCI index review, which removed GIANT BIOGENE from the MSCI China Index. The change will take effect after the close on November 30, pressuring near-term expectations for passive fund allocation.
Background fundamentals have already been soft. The company reported first-half revenue of RMB2.918 billion, down 6.3% year on year, while adjusted net profit fell 21.5% to RMB946 million. Earlier market commentary also said third-quarter performance was not encouraging enough, adding to pressure on the shares.
GIANT BIOGENE is a holding company focused on the research, manufacture and sale of beauty and health products based on bioactive ingredients, with business primarily concentrated in the domestic China market.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments